## Defining the roles of $Ca^{2+}$ entry in endothelin-1 and thromboxane $A_2$ receptor mediated vascular contractile responses

Y.Y. Chan, N. Scrimgeour, G.Y. Rychkov and <u>D.P. Wilson</u>, Discipline of Physiology, School of Medical Sciences, University of Adelaide, SA 5000, Australia.

**Introduction:**  $Ca^{2+}$  is an important mediator of vascular contractility, which can enter the cytosol through voltage-gated L- and T-channels and intracellular SR  $Ca^{2+}$  release. Upon depletion of the SR  $Ca^{2+}$  store,  $Ca^{2+}$ -release activated  $Ca^{2+}$  (CRAC) channels, which are composed of plasma membrane bound Orai1 and SR-bound STIM1, form functional channels, allowing store refilling. Although endothelin-1 (ET-1) and thromboxane  $A_2$  are both potent vasoconstrictors implicated in various vascular disease states, they mediate  $Ca^{2+}$  entry and vasoconstriction through uniquely different mechanisms.

**Aim and Method:** To identify the role of IP3 receptors, CRAC-, L- and T-channels in ET-1 and thromboxane  $A_2$ -mediated vasoconstriction. Using an *in vitro* rat artery model, functional vascular myography coupled with patch clamp analysis were used to identify the activation and inhibition of Ca<sup>2+</sup> entry pathways mediated by agonists and pharmacological inhibitors of ion channels, respectively.

**Results:** Brief sequestration of extracellular  $Ca^{2+}$  using EGTA (5mM) revealed that approximately 20% ET-1-mediated vasoconstriction involved IP3-mediated SR  $Ca^{2+}$  (p<0.05; n=4). Following SR  $Ca^{2+}$  depletion using cyclopiazonic acid (10mM) (a SERCA pump inhibitor) and 2-aminoethyl diphenyl borate (100mM) (which is known to block IP3 receptors, CRAC channels and potentially non-selective cation channels), vascular contractility was abrogated (P<0.05; n=4), indicating a role for both IP3 receptors and CRAC channels. Blocking extracellular  $Ca^{2+}$  entry using combined L-/T-channel blockers, mibefradil (1mM) (p<0.05; n=7) and efonidipine (0.021mM) (p<0.05; n=13) attenuated approximately 65% ET-1-mediated vasoconstriction in the microvasculature (Ball *et al.*, 2009). Patch clamp analysis of I<sub>CRAC</sub> has revealed that in addition to blocking L-and T-channels, both mibefradil and efonidipine also inhibited CRAC channels. In contrast, thromboxane A<sub>2</sub>-mediated vasoconstriction only involved  $Ca^{2+}$  entry through L-channels and RhoA-Rho kinase  $Ca^{2+}$ -independent sensitization and does not involve IP3 receptors, T or CRAC channels.

**Conclusion:** In the microvasculature, ET-1 mediates  $Ca^{2+}$  entry *via* L, T, IP3 receptors and CRAC channels. In contrast to the traditional L-type  $Ca^{2+}$  channel blockers, the more recently developed combined L-/T-channel blockers may provide additional benefit through blockade of CRAC channels, which may effectively enable clinical modulation of SR  $Ca^{2+}$  release.

Ball CJ, Wilson DP, Turner SP, Saint DA, Beltrame JF. (2009) Heterogeneity of L- and T-channels in the vasculature: Rationale for the efficacy of combined L- and T-blockade. *Hypertension* **53**: 654-660.